SHENZHEN, Chine, 10 avril 2024 /PRNewswire/ — Récemment, Kexing Biopharm (688136.SH) a annoncé que l’essai clinique de phase III de la solution d’inhalation d’interféron α1b humain développée par sa filiale à 100 %, Shenzhen Kexing Pharmaceutical Co., Ltd, avait terminé le recrutement du…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.